Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults
Pendrey AG, Rivera Sierra JA, Alvarez Lobo FA, et al.
Advances in therapy, 2026
Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review
Chan WK, Leung HK, Tan GJ, et al.
Journal of obesity & metabolic syndrome, 2026
Tirzepatide and risk of newly diagnosed aortic stenosis in patients with obesity: a multi-institutional real-world cohort study
Wu JY, Lee KW, Huang SC, et al.
BMC cardiovascular disorders, 2026
Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis
Sun WT, Liu RX, Jiang YH, et al.
Diabetes, obesity & metabolism, 2026
Retatrutide fact check: Has a man died after taking the unapproved weight loss jab?
Mahase E
BMJ (Clinical research ed.), 2026;394:e100245
GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis
Yang Z, Li X, Wu N, et al.
Stem cell reports, 2026;:103008
Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management?
Scilletta S, Di Marco M, Bosco G, et al.
Nutrition, metabolism, and cardiovascular diseases : NMCD, 2026;:104860
Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey
Gibble TH, Al-Zubeidi T, Gerber C, et al.
Obesity pillars, 2026;19:100298
Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies
Bijoch J
Journal of clinical medicine, 2026;15(14)
Holistic Management of Obesity in Patients with Incidental Cancer After Unprovoked Deep Vein Thrombosis: A Cardiometabolic and Antithrombotic Framework
Geraci C, Cannarella R, Morello V, et al.
Cancers, 2026;18(14)
Acute pancreatitis followed by leukocytoclastic vasculitis induced by tirzepatide: A first case report with this new medication
Zgolli F, Daly W, Aouinti I, et al.
Therapie, 2026
Oral Adverse Effects of Semaglutide Therapy: A Narrative Review
Al-Zawawi AS
Journal of International Society of Preventive & Community Dentistry, 2026;16(4):331-340
GLP-1 and MASH: When weight loss isn’t the whole story
Long MT, Krarup N, Knop FK
Cell metabolism;38(7):1258-1260
Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review
Bloomgarden Z
Journal of diabetes;18(7):e70248
Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis
Stogios N, Agarwal SM, Maksyutynska K, et al.
JAMA psychiatry, 2026
Disrupting the adiposopathy-inflammation loop: a translational immunometabolic framework for inflammatory disease
Corrao S
Journal of translational medicine, 2026
Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure
Mortada I, Paul K, Chammany M, et al.
Diabetes & vascular disease research, 2026;23(4):14791641261467888
Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists
Chen SC, Wang TJ, Chou CK, et al.
Diabetes, obesity & metabolism, 2026
Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes
Skandov MD, Christensen KM, Dalin DA, et al.
Diabetes, obesity & metabolism, 2026
Short-Term HbA1c Non-Inferiority of Synthetic Semaglutide Should Not Be Conflated With Full Therapeutic Interchangeability
Singh AK, Singh A, Singh R
Diabetes, obesity & metabolism, 2026